KR102408798B1 - 항진균성 건조 분말 - Google Patents

항진균성 건조 분말 Download PDF

Info

Publication number
KR102408798B1
KR102408798B1 KR1020197013649A KR20197013649A KR102408798B1 KR 102408798 B1 KR102408798 B1 KR 102408798B1 KR 1020197013649 A KR1020197013649 A KR 1020197013649A KR 20197013649 A KR20197013649 A KR 20197013649A KR 102408798 B1 KR102408798 B1 KR 102408798B1
Authority
KR
South Korea
Prior art keywords
dry powder
delete delete
formulation
itraconazole
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197013649A
Other languages
English (en)
Korean (ko)
Other versions
KR20190068591A (ko
Inventor
제이슨 엠. 페리
진 씨. 성
데이비드 엘. 하바
로버트 클리포드 사운더스
힐러리 에스. 트레이시
앤드류 에메트 오코너
Original Assignee
풀매트릭스 오퍼레이팅 컴퍼니, 인크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 풀매트릭스 오퍼레이팅 컴퍼니, 인크 filed Critical 풀매트릭스 오퍼레이팅 컴퍼니, 인크
Publication of KR20190068591A publication Critical patent/KR20190068591A/ko
Application granted granted Critical
Publication of KR102408798B1 publication Critical patent/KR102408798B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020197013649A 2016-10-14 2017-10-13 항진균성 건조 분말 Active KR102408798B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408376P 2016-10-14 2016-10-14
US62/408,376 2016-10-14
PCT/US2017/056497 WO2018071757A1 (en) 2016-10-14 2017-10-13 Antifungal dry powders

Publications (2)

Publication Number Publication Date
KR20190068591A KR20190068591A (ko) 2019-06-18
KR102408798B1 true KR102408798B1 (ko) 2022-06-13

Family

ID=60186406

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197013649A Active KR102408798B1 (ko) 2016-10-14 2017-10-13 항진균성 건조 분말

Country Status (12)

Country Link
US (3) US11116722B2 (OSRAM)
EP (1) EP3525759A1 (OSRAM)
JP (1) JP7085538B2 (OSRAM)
KR (1) KR102408798B1 (OSRAM)
CN (1) CN109996536B (OSRAM)
AU (1) AU2017341815B2 (OSRAM)
CA (1) CA3039485A1 (OSRAM)
IL (1) IL265913B2 (OSRAM)
MX (1) MX388733B (OSRAM)
NZ (1) NZ752353A (OSRAM)
RU (1) RU2766086C2 (OSRAM)
WO (1) WO2018071757A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107096014B (zh) * 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
CN112423755A (zh) * 2018-04-18 2021-02-26 希普拉技术有限责任公司 治疗真菌感染的方法
US20210145739A1 (en) * 2018-04-18 2021-05-20 Pulmatrix Operating Company, Inc. Antifungal formulations for pulmonary administration comprising itraconazole
WO2021092349A1 (en) * 2019-11-08 2021-05-14 Scynexis, Inc. Lipid-based formulations of scy-078 salts
CN111658610B (zh) * 2020-07-31 2022-05-24 上海方予健康医药科技有限公司 一种供雾化器用的三氮唑类抗真菌药物的混悬液
IT202000030437A1 (it) 2020-12-10 2022-06-10 Zambon Spa Metodo per la realizzazione di una polvere inalabile comprendente voriconazolo
IT202000030443A1 (it) 2020-12-10 2022-06-10 Zambon Spa Polvere inalabile comprendente voriconazolo in forma cristallina
WO2023086013A2 (en) * 2021-11-09 2023-05-19 Agency For Science, Technology And Research A salt-based antifungal powder platform formulation for aerosolization
EP4452235A1 (en) * 2021-12-20 2024-10-30 Pulmatrix Operating Company, Inc. Dry powder formulations of narrow spectrum kinase inhibitors
EP4539821A1 (en) 2022-06-21 2025-04-23 Hovione Scientia Limited Crystalline pharmaceutical composition for inhalation comprising sugar and lipid composite particles and process for manufacture
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
WO2024049982A2 (en) 2022-08-31 2024-03-07 Pulmatrix Operating Company, Inc. Methods of using itraconazole dry powders
WO2025064631A1 (en) * 2023-09-20 2025-03-27 The Board Of Trustees Of The University Of Illinois Use of a dry powder inhaler to treat or prevent pulmonary fungal infections

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4097620A (en) 1977-05-02 1978-06-27 Xerox Corporation Magnetic toner particle coating process
US4916134A (en) 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US6448401B1 (en) * 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
AU2002245181B2 (en) 2000-12-21 2006-06-29 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
ITMI20010357U1 (it) 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
AU2003302274A1 (en) 2002-12-31 2004-07-29 Novartis Ag Aerosolizable pharmaceutical formulation for fungal infection therapy
KR20120080243A (ko) 2003-05-28 2012-07-16 노바르티스 아게 아미노산 및/또는 인지질로 부분 또는 완전 코팅된 수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의 분무 건조법
WO2005009375A2 (en) 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
EP1789018A1 (en) 2004-08-27 2007-05-30 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
ITMI20051999A1 (it) 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
WO2007092088A1 (en) 2005-12-28 2007-08-16 Nektar Therapeutics Compositions comprising amphotericin b
BRPI0712130A2 (pt) * 2006-05-30 2012-01-17 Elan Pharma Int Ltd formulações de posaconazol em nanopartìculas
KR20090041426A (ko) 2006-08-11 2009-04-28 파나세아 바이오테크 리미티드 활성제를 전달하기 위한 미립자 및 이의 조제방법 및 조성물
EP2227085A4 (en) 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
NO2252275T3 (OSRAM) 2008-02-13 2018-04-28
EP2095816A1 (en) 2008-02-29 2009-09-02 Schlichthaar, Rainer, Dr. Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety
EP2172193A1 (en) 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
US9061352B2 (en) * 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
EA032840B8 (ru) 2011-06-22 2020-06-18 Вайоми Терапеутикс Лимитед Пролекарства на основе конъюгатов противогрибковых агентов и их применение
EP2601973A1 (en) * 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
US20180369513A1 (en) 2012-02-21 2018-12-27 Respira Therapeutics, Inc. Powder dispersion devices and methods
US10525216B2 (en) * 2012-02-21 2020-01-07 Respira Therapeutics, Inc. Powder dispersion methods and devices
IN2012DE00674A (OSRAM) 2012-03-07 2015-08-21 Nat Inst Of Pharmaceutical Education And Res Niper
WO2014106727A1 (en) 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014165303A1 (en) * 2013-04-01 2014-10-09 Pulmatrix, Inc. Tiotropium dry powders
CN104398497B (zh) * 2014-10-29 2017-11-24 中山大学 伊曲康唑吸入粉雾剂及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Christophe Duret, et al., International Journal of Nanomedicine, 2012, 7, 5475-5489. (2012.10.17.)*
공개특허공보 제10-2003-0067718호 (2003.08.14.)*

Also Published As

Publication number Publication date
US11116722B2 (en) 2021-09-14
RU2019114112A (ru) 2020-11-16
RU2766086C2 (ru) 2022-02-07
AU2017341815B2 (en) 2023-06-15
US20200129428A1 (en) 2020-04-30
KR20190068591A (ko) 2019-06-18
US20250221928A1 (en) 2025-07-10
WO2018071757A1 (en) 2018-04-19
AU2017341815A1 (en) 2019-05-02
CN109996536A (zh) 2019-07-09
IL265913B1 (en) 2024-03-01
NZ752353A (en) 2023-06-30
US20240285523A1 (en) 2024-08-29
MX388733B (es) 2025-03-20
MX2019004322A (es) 2019-12-11
BR112019007459A2 (pt) 2019-07-16
JP7085538B2 (ja) 2022-06-16
CA3039485A1 (en) 2018-04-19
IL265913A (en) 2019-06-30
EP3525759A1 (en) 2019-08-21
RU2019114112A3 (OSRAM) 2021-02-12
CN109996536B (zh) 2023-03-07
JP2019534270A (ja) 2019-11-28
IL265913B2 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
US20240285523A1 (en) Antifungal dry powders
JP7549534B2 (ja) イトラコナゾールを含む肺内投与のための抗真菌配合物
US20190167579A1 (en) Itraconazole dry powders
AU2019256453B2 (en) Methods of treating fungal infections
CN116687887A (zh) 用于吸入的干粉制剂
US20250049717A1 (en) Dry powder formulations of narrow spectrum kinase inhibitors
US20240033218A1 (en) Dihydroergotamine dry powder formulations and methods of use
RU2820457C2 (ru) Способы лечения грибковых инфекций
BR112019007459B1 (pt) Pós secos antifúngicos e uso dos mesmos
WO2024040175A1 (en) Methods for treating cancer using inhaled angiogenesis inhibitor
NZ793053A (en) Antifungal dry powders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190513

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201013

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210617

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210617

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211129

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210817

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201013

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20220315

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20220228

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20211129

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210817

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20201013

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220609

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220609

End annual number: 3

Start annual number: 1

PG1601 Publication of registration